InDex Pharmaceuticals has filed five more patents that will further strengthen its
extensive portfolio of proprietary intellectual assets.
“We have complemented our IP assets with some important patents that will add
protection to our potential treatments of different diseases related to the immune
system”, commented Svante Rasmuson, CEO of InDex Pharmaceuticals. “These five
patents are all connected to our collection of proprietary DIMS substances (DNA-based
Immunomodulatory Sequences) that we believe will be the base of our future
immunotherapy franchise.”
In total, InDex has filed up to 20 patents that are related either to its pharmaceutical
research and development activities or its novel technology of diagnostics used for
classification of gastrointestinal diseases.
Details of the new patents:
MS therapy
This patent application relates to novel compounds and methods of use for the treatment
of MS. It relates in particular to methods to treat MS patients with DIMS compounds that
are designed to induce high levels of endogenous interferon-ß.
PMN inhibition
This patent application relates to novel compounds and methods of use for the treatment
and thereby reduction of ischemic tissue and/or organ damage. It relates in particular to
methods of use of specific DIMS compounds to prevent migration of immune cells to
ischemic areas.
CD20, CD23 and CD80 expression
As expansions to previously filed cancer combination therapy patents, these patent
applications relate to novel DIMS compounds and methods of use as treatment
enhancers of antibody therapies that target specific receptors present on immune cells
